{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:00:04Z","timestamp":1782943204307,"version":"3.54.5"},"reference-count":79,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,8,12]],"date-time":"2002-08-12T00:00:00Z","timestamp":1029110400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Apheresis"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Current reimbursement policy of health insurance for therapeutic plasmapheresis requires proof of efficacy using the concept of <jats:italic>evidence\u2010based medicine.<\/jats:italic> The aim of this paper is to review the outcome of plasmapheresis used to treat thrombotic microangiopathy (TMA)\u2010associated syndromes in the last decade to provide scientific evidence to back up reimbursement applications. The strength of evidence of each reviewed study was assessed using the five levels of evidence criteria as defined by the American Society of Hematology in 1996 for assessment of the treatment of immune thrombocytopenia. The level <jats:italic>Experimental indication<\/jats:italic> was added for situations where only case reports or small series supported by pathophysiological reasoning are available. The definitions of evidence used in this paper are as follows: Level I, randomized clinical trial with low rates of error (p &lt; 0.01); Level II, randomized clinical trial with high rates of error (p &lt; 0.05); Level III, nonrandomized studies with concurrent control group; Level IV, nonrandomized studies with historical control group; Level V, case series without a control group or expert opinion; and Experimental, case reports and pathophysiological reasoning. The results of this analysis based on the published data is summarized as follows: The indication of plasmapheresis is assigned to Level IV evidence for thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS); cancer\/chemotherapy\u2010associated TTP\/HUS is assigned to Level V evidence; and TTP\/HUS refractory to standard plasma exchange and post\u2010bone marrow transplantation TTP\/HUS are assigned to <jats:italic>Experimental indication.<\/jats:italic> For both subsets, protein A immunoadsorption is reportedly successful. The other TMA\u2010associated syndromes, hemolysis elevated liver enzymes low platelets and HUS in early childhood, are no indication of plasmapheresis. Two randomized clinical trials were performed in order to demonstrate the superiority of plasma exchange\/fresh frozen plasma (PEX\/FFP) over plasma transfusion in the management of TTP\/HUS. The results prove the greater clinical success of the latter type of plasma administration. Standard PEX\/FFP has reduced the mortality of TTP\/HUS from 94.5% to 13%.<\/jats:p>","DOI":"10.1046\/j.1526-0968.2002.00390.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:01:41Z","timestamp":1047502901000},"page":"320-328","source":"Crossref","is-referenced-by-count":73,"title":["Plasmapheresis in Thrombotic Microangiopathy\u2010Associated Syndromes: Review of Outcome Data Derived from Clinical Trials and Open Studies"],"prefix":"10.1111","volume":"6","author":[{"given":"Hans","family":"Von Baeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,8,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70310-5"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.","volume":"88","author":"George JN","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_4_2","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.","volume":"24","author":"Moschcovitz E","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"e_1_2_6_5_2","first-page":"905","article-title":"H\u00e4molytisch ur\u00e4mische Syndrome: Bilaterale Nierenrindennekrose bei akuten erworbenen h\u00e4molytischen An\u00e4mien.","volume":"85","author":"Gasser C","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)32330-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.206"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996101"},{"key":"e_1_2_6_9_2","first-page":"98","article-title":"Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura\/sporadic hemolytic uremic syndrome.","volume":"34","author":"Laurence J","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_10_2","first-page":"90","article-title":"Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura.","volume":"34","author":"Smith BR","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_11_2","first-page":"83","article-title":"Studies on the pathophysiology of thrombotic thrombocytopenic purpura.","volume":"34","author":"Moake JL","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198212023072306"},{"key":"e_1_2_6_13_2","first-page":"300","article-title":"Pathophysiology and management of thrombotic microangiopathies.","volume":"11","author":"Ruggenenti P","year":"1998","journal-title":"J Nephrol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.","volume":"87","author":"Furlan M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.","volume":"87","author":"Tsai HM","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80064-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392202"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood.V93.11.3798","article-title":"von Willebrand factor proteolysis is deficient in classic but not in bone marrow transplantation\u2010associated thrombotic thrombocytopenic purpura.","volume":"93","author":"Van der Plas RM","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050383"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80062-0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994923"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199811150-00024"},{"key":"e_1_2_6_23_2","first-page":"126","article-title":"Transplantation\u2010associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.","volume":"34","author":"Schriber JR","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_24_2","first-page":"193","article-title":"Thrombotic microangiopathy as a complication of high\u2010dose chemotherapy for breast cancer.","volume":"18","author":"Fisher DC","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_25_2","first-page":"117","article-title":"Human immunodeficiency virus infection and thrombotic microangiopathy.","volume":"34","author":"Hymes KB","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_26_2","first-page":"1469","article-title":"Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era.","volume":"19","author":"Stricker RB","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.495"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.1998.00140.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<11::AID-AJH3>3.0.CO;2-8"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1101(2000)15:3<176::AID-JCA4>3.0.CO;2-T"},{"key":"e_1_2_6_31_2","first-page":"148","article-title":"Thrombotic microangiopathy during pregnancy.","volume":"34","author":"McCrea KR","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_32_2","first-page":"119","article-title":"Thrombotic microangiopathy in pregnancy and the postpartum period.","volume":"24","author":"Weiner CP","year":"1987","journal-title":"Semin Hematol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:2<69::AID-JCA4>3.0.CO;2-R"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410807"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197712222972507"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.","volume":"50","author":"Bukowski RM","year":"1977","journal-title":"Blood"},{"key":"e_1_2_6_37_2","first-page":"159","article-title":"Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.","volume":"34","author":"Kwaan HC","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_38_2","first-page":"134","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.","volume":"34","author":"Bell WR","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199706)55:2<55::AID-AJH1>3.0.CO;2-1"},{"key":"e_1_2_6_40_2","first-page":"711","article-title":"Response of refractory thrombotic thrombocytopenic purpura to extracorporeal immunoadsorption.","volume":"236","author":"Mittelman A","year":"1992","journal-title":"N Engl J Med"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920090302"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70316-5"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<120::AID-JCA5>3.0.CO;2-E"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050012"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<102::AID-AJH2>3.0.CO;2-0"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830340303"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420214"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archinte.1994.00420090056006","article-title":"Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome.","volume":"154","author":"Hayward CP","year":"1994","journal-title":"Arch Int Med"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250605"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920060305"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1996)11:4<173::AID-JCA1>3.0.CO;2-8"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:1<9::AID-JCA2>3.0.CO;2-3"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00286-7"},{"key":"e_1_2_6_57_2","first-page":"1761","article-title":"Traitement du purpura thrombotique thrombop\u00e9nique: R\u00e9sultats d\u2018une \u00e9tude cliniques multicentric randomis\u00e9e.","volume":"20","author":"Henon PH","year":"1991","journal-title":"Presse M\u00e9dical"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-196603000-00003"},{"key":"e_1_2_6_60_2","unstructured":"Hennekens CH Buring JE. Intervention studies. In: Mayrent SL ed.Epidemiology in medicine.Boston\/Toronto: Little Brown and Company 1987:178."},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-7-199804010-00004"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.3.311"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422402"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199601)51:1<1::AID-AJH1>3.3.CO;2-I"},{"key":"e_1_2_6_65_2","first-page":"58","article-title":"Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption.","volume":"47","author":"D'Souza RF","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_66_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.","volume":"85","author":"Fung MC","year":"1999","journal-title":"Cancer"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199911150-00020"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199608)52:4<310::AID-AJH11>3.3.CO;2-H"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199902270-00009"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.1999.00170.x"},{"key":"e_1_2_6_71_2","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood.V80.8.1890.bloodjournal8081890","article-title":"Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.","volume":"80","author":"Thompson CE","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830400206"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470407"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)80030-5"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994683"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920090303"},{"key":"e_1_2_6_77_2","first-page":"405","article-title":"Hemolytic uremic syndrome following bone marrow transplantation.","volume":"7","author":"Juckett M","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_78_2","first-page":"247","article-title":"Bone marrow transplant\u2010associated thrombotic microangiopathy: a case series.","volume":"15","author":"Zeigler ZR","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1996)11:4<176::AID-JCA2>3.0.CO;2-8"},{"key":"e_1_2_6_80_2","first-page":"271","article-title":"Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome following bone marrow transplantation.","volume":"16","author":"Sarode R","year":"1995","journal-title":"Bone Marrow Transplant"}],"container-title":["Therapeutic Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-0968.2002.00390.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2002.00390.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:30:58Z","timestamp":1697239858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-0968.2002.00390.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1046\/j.1526-0968.2002.00390.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-0968.2002.00390.x","archive":["Portico"],"relation":{},"ISSN":["1091-6660","1526-0968"],"issn-type":[{"value":"1091-6660","type":"print"},{"value":"1526-0968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}